MA-IBASIS
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Sequans Communications S.A. (NYSE: SQNS), a leading developer and provider of 5G/4G chips and modules, today announced that Actility, a leading provider of IoT connectivity platform, has chosen iBASIS and Sequans to roll out programmable cellular IoT solutions with eSIM and iSIM.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005808/en/
Actility had previously worked closely with iBASIS to enable roaming between private unlicensed networks powered by ThingPark EPC Connector and public networks, using Simfony’s CMP platform, now fully integrated with iBASIS’ Global Access for Things™ IoT portfolio. The longstanding partnership between iBASIS and Sequans has produced several successful proofs of concept.
The new ultra-low-power multi-technology trackers of Abeeway, a fully owned Actility subsidiary, will benefit from Sequans Monarch 2 LTE-M/NB-IoT platform with integrated iSIM and the connectivity profile provided by iBASIS, allowing the device to connect to cellular networks worldwide. Actility will also benefit from Sequans Monarch 2 being the first iSIM implementation that has achieved common criteria EAL5+ certification, allowing the use of iBASIS’ intelligent profile selection technology with remote update using multiple Tier-1 operator profiles as provided for eSIM.
iSIM is fully integrated in the cellular modem and microcontroller unit on a single system on chip (SoC). It relies on the existing eSIM infrastructure accessing 2/3/4/5G networks using the global footprint of iBASIS. iSIM is considered to be the future of connectivity technology for many IoT deployments.
An important step forward in the IoT industry, iSIM will positively influence device design in the areas of space optimization, and reduction of energy and power consumption. By eliminating the need for a separate SIM chip, iSIM will provide the customer with a more streamlined supply chain experience when manufacturing a device using cellular connectivity. The entire supply chain will benefit from the reduction of materials which will lead to lower costs for manufacturers.
According to Counterpoint Research, beyond 2027 iSIM is projected to take over as the dominant SIM form factor, with the shipments of iSIM-capable devices poised to scale to 7 billion units between 2021 and 2030.
With the iBASIS Global Access for Things™ industry-leading coverage, eSIM/iSIM enables enterprises to easily adopt a single global, remotely programmable SIM that provides mobile data connectivity to smart devices all over the world.
“After recent collaboration with iBASIS, adding iBASIS connectivity on our Monarch 2 module with eSIM, and having fully tested the global connectivity on iSIM, we are now advancing into an integrated production phase driven by a customer need,” said Louis Chuang, EVP of Sequans’ Massive IoT Business Unit. “We are thrilled to reach this important milestone with iBASIS whereby we can offer customers a powerful iSIM capability, along with low power consumption, cost-efficiency, and GNSS support.”
“After being recognized as a leader in the cellular IoT connectivity market with eSIMs, we are delighted to implement iSIM technology together with our trusted partner Sequans,” said Ajay Joseph, CEO IoT & CTO, iBASIS. “After many years of research and development, while deploying iSIM technology in trial environments, it is a great achievement by our teams. This once again underlines that iBASIS is a frontrunner and truly lives by its motto: ‘Be there first’. We strongly believe that iSIM will become a dominant factor within the IoT industry and I am proud to see that we are now able to provide our longstanding customer Actility with our proven IoT connectivity on iSIM.”
“Our focus is ultra-low-power industrial IoT connectivity. The new cellular trackers of our subsidiary Abeeway leverage LTE-M and NB-IoT, and our ThingPark EPC Connector for unlicensed private cellular networks (such as CBRS) rely on recent 3GPP slicing technologies,” said Olivier Hersent, CEO of Actility. “We needed cutting edge partners to support reliable LTE-M connections with PSM/eDRX options in permanent roaming as well as iSIMs: after extensive testing we selected Sequans for their ability to support iSIMs and because 100 percent of their software stack is developed in-house, and iBASIS for their ability to support complex integration and their focus on quality, based on proactive testing. Together, I think we form the dream team for industrial low-power IoT.”
To find out more, visit iBASIS in Hall 2, MR 2A6 and 2A8, and Sequans in Hall 5, Stand 5H40, at Mobile World Congress from February 27 to March 2 in Barcelona.
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player and IoT solution provider. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. iBASIS today serves 1,000+ customers across 26 offices worldwide. For more information, please visit iBASIS.com.
ABOUT SEQUANS
Sequans Communications S.A. (NYSE: SQNS) is a leading developer and supplier of cellular IoT connectivity solutions, providing chips and modules for 5G/4G massive and broadband IoT. For 5G/4G massive IoT applications, Sequans provides a comprehensive product portfolio based on its flagship Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms, featuring industry-leading low power consumption, a large set of integrated functionalities, and global deployment capability. For 5G/4G broadband IoT applications, Sequans offers a product portfolio based on its Cassiopeia Cat 4/Cat 6 4G and high-end Taurus 5G chip platforms, optimized for low-cost residential, enterprise, and industrial applications. Founded in 2003, Sequans is based in Paris, France with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Finland, Taiwan, South Korea, and China. Visit Sequans online at www.sequans.com, and follow us on Twitter and LinkedIn.
ABOUT ACTILITY
Actility is the world leader in Low-Power Wide-Area Networks (LPWAN) industrial-grade connectivity solutions for the Internet of Things. Actility provides its ThingPark™ platform and network technology to deploy, operate and maintain public and private wireless IoT networks within a unified, scalable and versatile network infrastructure. The vast majority of nationwide LPWAN network service providers and hundreds of enterprises trust ThingPark™ all over the world. Through its subsidiary Abeeway, Actility also provides patented ultra-low power tracking solutions. ThingPark Market offers the largest selection of interoperable IoT gateways, devices and applications to simplify and accelerate deployment of numerous use cases. Contact us here: https://www.actility.com/contact
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005808/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom